The advantages of array coil imaging in human whole-body MR systems are well known and have gained relevance in many applications and MR techniques. In the field of small-animal studies, this concept has become increasingly important. In this work, three different phased-array coils for performing MRI on mice are presented. For imaging at 300 MHz, a four-channel receive-only phased-array coil is introduced. One two-channel and a four-channel transmit/receive setup operating at 750 MHz show the feasibility of array coil imaging at 17.6 T. All of these coils show excellent performance and deliver high-quality MR images of mice.
PurposeCardiac phosphorus magnetic resonance spectroscopy (31P-MRS) provides unique insight into the mechanisms of heart failure. Yet, clinical applications have been hindered by the restricted sensitivity of the surface radiofrequency-coils normally used. These permit the analysis of spectra only from the interventricular septum, or large volumes of myocardium, which may not be meaningful in focal disease. Löring et al. recently presented a prototype whole-body (52 cm diameter) transmit/receive birdcage coil for 31P at 7T. We now present a new, easily-removable, whole-body 31P transmit radiofrequency-coil built into a patient-bed extension combined with a 16-element receive array for cardiac 31P-MRS.Materials and methodsA fully-removable (55 cm diameter) birdcage transmit coil was combined with a 16-element receive array on a Magnetom 7T scanner (Siemens, Germany). Electro-magnetic field simulations and phantom tests of the setup were performed. In vivo maps of B1+, metabolite signals, and saturation-band efficiency were acquired across the torsos of eight volunteers.ResultsThe combined (volume-transmit, local receive array) setup increased signal-to-noise ratio 2.6-fold 10 cm below the array (depth of the interventricular septum) compared to using the birdcage coil in transceiver mode. The simulated coefficient of variation for B1+ of the whole-body coil across the heart was 46.7% (surface coil 129.0%); and the in vivo measured value was 38.4%. Metabolite images of 2,3-diphosphoglycerate clearly resolved the ventricular blood pools, and muscle tissue was visible in phosphocreatine (PCr) maps. Amplitude-modulated saturation bands achieved 71±4% suppression of phosphocreatine PCr in chest-wall muscles. Subjects reported they were comfortable.ConclusionThis easy-to-assemble, volume-transmit, local receive array coil combination significantly improves the homogeneity and field-of-view for metabolic imaging of the human heart at 7T.
Purpose:To assess the feasibility of half-Fourier-acquisition single-shot turbo spin-echo (HASTE) of the lung at 3 Tesla (T) using parallel imaging with a prototype of a 32-channel torso array coil, and to determine the optimum acceleration factor for the delineation of intrapulmonary anatomy. Materials and Methods:Nine volunteers were examined on a 32-channel 3T MRI system using a prototype 32-channeltorso-array-coil. HASTE-MRI of the lung was acquired at both, end-inspiratory and end-expiratory breathhold with parallel imaging (Generalized autocalibrating partially parallel acquisitions ϭ GRAPPA) using acceleration factors ranging between R ϭ 1 (TE ϭ 42 ms) and R ϭ 6 (TE ϭ 16 ms). The image quality of intrapulmonary anatomy and subjectively perceived noise level was analyzed by two radiologists in consensus. In addition quantitative measurements of the signalto-noise ratio (SNR) of HASTE with different acceleration factors were assessed in phantom measurements. Results:Using an acceleration factor of R ϭ 4 image blurring was substantially reduced compared with lower acceleration factors resulting in sharp delineation of intrapulmonary structures in expiratory scans. For inspiratory scans an acceleration factor of 2 provided the best image quality. Expiratory scans had a higher subjectively perceived SNR than inspiratory scans. Conclusion:Using optimized multi-element coil geometry HASTE-MRI of the lung is feasible at 3T with acceleration factors up to 4. Compared with nonaccelerated acquisitions, shorter echo times and reduced image blurring are achieved. Expiratory scanning may be favorable to compensate for susceptibility associated signal loss at 3T.
Purpose: To use the contrast agent gadofosveset for absolute quantification of myocardial perfusion and compare it with gadobenate dimeglumine (Gd-BOPTA) using a high-resolution generalized autocalibrating partially parallel acquisition (GRAPPA) sequence. Materials and Methods:Ten healthy volunteers were examined twice at two different dates with a first-pass perfusion examination at rest using prebolus technique. We used a 1.5 T scanner and a 32 channel heart-array coil with a steady-state free precession (SSFP) true fast imaging with steady state precession (trueFISP) GRAPPA sequence (acceleration-factor 3). Manual delineation of the myocardial contours was performed and absolute quantification was performed after baseline and contamination correction. At the first appointment, 1cc/4cc of the extracellular contrast agent Gd-BOPTA were administered, on the second date, 1cc/4cc of the blood pool contrast agent (CA) gadofosveset. At each date the examination was repeated after a 15-minute time interval.Results: Using gadofosveset perfusion the value (in cc/g/ min) at rest was 0.66 6 0.25 (mean 6 standard deviation) for the first, and 0.55 6 0.24 for the second CA application; for Gd-BOPTA it was 0.62 6 0.25 and 0.45 6 0.23. No significant difference was found between the acquired perfusion values. The apparent mean residence time in the myocardium was 23 seconds for gadofosveset and 19.5 seconds for Gd-BOPTA. Neither signal-to-noise ratio (SNR) nor subjectively rated image contrast showed a significant difference. Conclusion:The application of gadofosveset for an absolute quantification of myocardial perfusion is possible. Yet the acquired perfusion values show no significant differences to those determined with Gd-BOPTA, maintained the same SNR and comparable perfusion values, and did not picture the expected concentration time-course for an intravasal CA in the first pass.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.